To Receive Us$10 Million Milestone Payment From Abbvie Under Collaboration Targeting Neurological Diseases
20/04/2026 07:32
April 20 (Reuters) - Nxera Pharma Co Ltd 4565.T: NXERA PHARMA CO LTD - TO RECEIVE US$10 MILLION MILESTONE PAYMENT FROM ABBVIE UNDER COLLABORATION TARGETING NEUROLOGICAL DISEASES Source text: ID:nTSpt7bb60 Further company coverage: 4565.T
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up